Yonce v. Smithkline Beecham Clinical Laboratories, Inc.

680 A.2d 569, 111 Md. App. 124, 1996 Md. App. LEXIS 107
CourtCourt of Special Appeals of Maryland
DecidedJune 28, 1996
Docket1560, Sept. Term, 1995
StatusPublished
Cited by27 cases

This text of 680 A.2d 569 (Yonce v. Smithkline Beecham Clinical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Court of Special Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yonce v. Smithkline Beecham Clinical Laboratories, Inc., 680 A.2d 569, 111 Md. App. 124, 1996 Md. App. LEXIS 107 (Md. Ct. App. 1996).

Opinion

EYLER, Judge.

The premature births, and untimely deaths, of monozygotic (identical) twins born to appellants Deborah and Dennis Yonce gave rise to the litigation presently before us. Suit was brought by appellants as personal representatives of the deceased infants' estates, as parents for the wrongful deaths of their two minor children, by Deborah Yonce individually, and by appellants jointly for loss of consortium. They filed suit on September 22, 1993 in the Circuit Court for Baltimore City against SmithKline Beecham Corporation and two of its subsidiaries, appellees (“SmithKline”), 1 and, on or about the same date, filed an action in the Health Claims Arbitration Office against Roger C. Sanders, M.D., et al., appellee (“Sanders”). 2 On November 2, 1993, SmithKline removed the case to the United States District Court for the District of Maryland. Thereafter, following a waiver of arbitration, appellants petitioned the United States District Court for leave to amend their complaint to add Sanders as a defendant. The claims against Sanders were based on negligence, and the claims against SmithKline were based on negligence and breach of contract. In an order dated August 9, 1994, the United States District Court granted the petition, thereby destroying diver *128 sity of citizenship and, accordingly, remanded the matter to the circuit court.

SmithKline filed a motion for summary judgment with respect to all counts pertaining to it. The motion and memorandum in support thereof asserted lack of proximate cause and assumption of the risk as defenses to the tort counts; with respect to the contract counts, it asserted that Deborah Yonce was not a third-party beneficiary of a contract between Sanders and SmithKline and the alleged damages were not legally recoverable in a contract action. The circuit court heard argument on all of these issues in December of 1994. On January 24, 1995, the circuit court issued a memorandum opinion in which it concluded that SmithKline was entitled to summary judgment. Although the circuit court granted summary judgment in favor of SmithKline with respect to all counts (negligence and contract), in its opinion the circuit court referred only to the negligence claims and to the defense of proximate cause. 3 On February 13, 1995, appellants filed a motion requesting the circuit court to enter a final judgment pursuant to Maryland Rule 2-602. 4 The circuit court denied the motion on March 17, 1995. Appellants then filed a motion for reconsideration, in which they reiterated, among other things, that none of the defendants opposed appellants’ motion for entry of a final judgment. The circuit court, nevertheless, denied that motion on April 24, 1995. Subsequently, Sanders moved for summary judgment on the ground of lack of proximate cause, based on the circuit court’s judgment en *129 tered on behalf of SmithKline. In August of that year, the circuit court granted Sanders’ motion for summary judgment.

Unsatisfied with the events that transpired below, appellants noted an appeal from the entry of summary judgment in favor of SmithKline and Sanders, and pose three question to us: 5

I. Can the admittedly negligent destruction of a medical sample be a proximate cause of damages sustained as a result of a subsequent medical procedure required to obtain a replacement sample?
II. Where a defendant negligently destroys a medical sample, does the patient ‘voluntarily’ encounter the risks associated with a subsequent medical procedure required to obtain a replacement sample, for purposes of the doctrine of assumption of the risk?
III. Where a defendant negligently destroys a medical sample, is the patient’s ‘understanding and appreciation’ of the risks associated with the second procedure properly a genuine issue of material fact to be resolved by a jury?

Sometime in May of 1990, appellant Deborah Yonce learned that she was pregnant. 6 On June 29, 1990, Ms. Yonce went to the offices of Doctors Glowacki, Elberfeld & Spangler, P.A., Inc. (“Clinic”), for prenatal care and met with Shirley Secrest, a certified nurse midwife. In her deposition, Ms. Yonce testified that she could not recall the content of her conversation with Secrest. Secrest stated, in an affidavit, that she counseled Ms. Yonce regarding amniocentesis 7 and chorionic *130 villus sampling (“CVS”) 8 and, although she could not recall the actual conversation, she followed her normal routine and detailed the risks attendant to an advanced maternal age delivery (thirty-five years or over). 9 On July 9, 1990, Ms. *131 Yonce returned to the Clinic and met with Dr. Spangler. According to Ms. Yonce, Dr. Spangler discussed with her the potential hazards associated with her pregnancy (e.g., chromosomal abnormalities), explained to her the various testing options and attendant risks, including amniocentesis and CVS, and gave her assorted medical literature pertaining to the subjects under discussion. 10

*132 Approximately one month later, Ms. Yonce telephoned the Clinic and informed the office staff that she wished to have an amniocentesis performed. Ms. Yonce, who understood that the procedure was indicated, but elective, had discussed the matter with her husband and weighed the risks involved. She testified in her deposition as follows:

Q What was the nature of discussion that you had with your husband concerning amniocentesis?
A Which test to have, the amniocentesis or the CVS? The CVS didn’t seem to be as safe. The percentages and the possible outcome seemed not as, it didn’t seem as safe to have the CVS as what it did the amniocentesis, so we decided on the amniocentesis.

*133 Ms. Yonce’s amniocentesis was delayed from the scheduled date of September 5 because a sonogram conducted on that day revealed that she was carrying twins and the sonographers could not determine whether the twins were enveloped within one amniotic sac or separate sacs. Three more failed attempts at visualizing sac separation led Dr. Elberfeld, of the Clinic, to refer Ms. Yonce to Dr. Sanders and his Institute.

Ms. Yonce met with Dr. Sanders at the Institute on September 26, 1990, where they discussed, as he noted in his deposition, the reasons for conducting an amniocentesis and the risks associated with the procedure.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Walton v. Premier Socer Club
Court of Special Appeals of Maryland, 2024
Street v. Upper Chesapeake Med. Ctr.
Court of Special Appeals of Maryland, 2024
Brown v. State Farm Mut. Auto. Ins.
Court of Special Appeals of Maryland, 2023
Blake v. Chadwick
249 Md. App. 696 (Court of Special Appeals of Maryland, 2021)
Dowling v. A.R.T. Inst. of Wash., Inc.
372 F. Supp. 3d 274 (D. Maryland, 2019)
Marrick Homes LLC v. Rutkowski
161 A.3d 53 (Court of Special Appeals of Maryland, 2017)
Asphalt & Concrete Services, Inc. v. Perry
108 A.3d 558 (Court of Special Appeals of Maryland, 2015)
Asphalt & Concrete Serv's v. Perry
Court of Special Appeals of Maryland, 2014
Pittway Corp. v. Collins
973 A.2d 771 (Court of Appeals of Maryland, 2009)
Collins v. Li
933 A.2d 528 (Court of Special Appeals of Maryland, 2007)
Sindler v. Litman
887 A.2d 97 (Court of Special Appeals of Maryland, 2005)
Jordan v. Western Distributing Co.
135 F. App'x 582 (Fourth Circuit, 2005)
Moore v. Myers
868 A.2d 954 (Court of Special Appeals of Maryland, 2005)
Mole v. Jutton
846 A.2d 1035 (Court of Appeals of Maryland, 2004)
Oxendine v. Merck & Co.
236 F. Supp. 2d 517 (D. Maryland, 2002)
Oxendine v. Merck and Co., Inc.
236 F. Supp. 2d 517 (D. Maryland, 2002)
Mayer v. NORTH ARUNDEL HOSPITAL ASS'N
802 A.2d 483 (Court of Special Appeals of Maryland, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
680 A.2d 569, 111 Md. App. 124, 1996 Md. App. LEXIS 107, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yonce-v-smithkline-beecham-clinical-laboratories-inc-mdctspecapp-1996.